In addition, we are currently exploring strategies to increase tumor cell-selectivity of monobodies by fusion with FN3-based tumor-targeting moieties, that bind PD-L1 or EGFR (Hackel et al., 2012; Donnelly et al., 2018; Hantschel lab, unpublished results). This evidence concerns the gene EGFR and neoplasm.